CANNABIS BIOSCIENCE INTERNATION
0.0004+0.00 (+12.5%)
Oct 28, 4:00:00 PM EDT · OTC Markets OTCPK · CBIH · USD
Key Stats
Market Cap
5.23MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
10-Q
Q3 FY2025 results
Cannabis Bioscience International Holdings posted Q3 FY2025 revenue of $14,931, down 59% y/y from $36,411, while YTD revenue climbed 55% y/y to $268,066, driven by clinical trials that made up 99% of the total. Gross loss hit $4,465 in the quarter from elevated costs, yet YTD gross profit rose to $232,505 on steady expenses; operating loss narrowed to $141,344 (q/q derived) from $159,971 y/y, with net loss at $192,443 versus $209,192 prior year, the gap widened by derivative changes and interest but offset by debt forgiveness. Diluted EPS held at $(0.00002), aligning with 10.7B weighted shares. Cash dwindled to $548 amid $209,653 operating outflow, offset by $209,445 financing inflows including related-party loans; total debt stood at ~$1.2M, featuring SBA EIDL at 3.75% over 30 years and short-term notes up to 42.5%, with $584,776 related-party payables. No non-GAAP metrics disclosed in the 10-Q. Customer concentration persists, with three clients supplying 96% of YTD revenue.
8-K
Director buys 250M shares
Cannabis Bioscience International Holdings issued 250 million common shares to director John Jones on December 27, 2024, for $75,000 at $0.0003 per share, in a conflicting interest transaction approved by disinterested board members. The deal includes a repurchase covenant if shares fall below $93,750 value by December 31, 2025, terminable if average price tops $0.000375. This injects modest capital but ties the company to potential future obligations.
10-Q
Q2 FY2025 results
Cannabis Bioscience International Holdings posted Q2 FY2025 revenue of $74,248, up 16.5% y/y from $63,748, driven by clinical trials that hit $73,781. Gross profit climbed to $66,445 on lower costs, yet operating expenses of $126,072 yielded a $59,627 loss—better than last year's $94,512. Net loss narrowed to $79,528, or $(0.000008) per diluted share on 10.5B shares, with the gap from operating loss tied to $11,200 note discount and $8,701 interest. Cash edged to $1,002, propped by $102,750 financing against $102,503 operating burn; total debt sits at $1.2M including SBA loans at 3.75%. Revenue hinges on two customers for 98%. Controls falter, risking reporting slips.
8-K
Board expands with M&A expert
Cannabis Bioscience International Holdings expanded its board to four members on November 22, 2024, appointing Charles Tamburello effective December 1, 2024, for his mergers and acquisitions expertise from leading Global Discovery Group. Tamburello receives 100,000,000 common shares with no cash pay, but must forfeit portions if removed for cause or resigning before November 30, 2025. The board also formed an Executive Committee on November 15, 2024, vesting it with broad management powers while barring key actions like share issuances. This bolsters strategic deal-making, yet ties director retention to performance.
ACB
Aurora Cannabis Inc.
5.01-0.08
CBDL
CBD Life Sciences Inc.
0.00-0.00
CBSTF
THE CANNABIST COMPANY HOLDINGS
0.09+0.00
CRLBF
Cresco Labs Inc.
1.20-0.04
CURLF
Curaleaf Hldgs Inc.
2.82-0.05
CVSI
CV Sciences, Inc.
0.03-0.01
CWBHF
Charlotte's Web Holdings Inc.
0.16+0.00
IGPK
Integrated Cannabis Solutions,
0.00-0.00
JUSHF
Jushi Holdings Inc.
0.66-0.04
NXEN
Nexien BioPharma, Inc.
0.01+0.00